Published online Jan 21, 2018. doi: 10.3748/wjg.v24.i3.338
Peer-review started: November 9, 2017
First decision: November 30, 2017
Revised: December 6, 2017
Accepted: December 12, 2017
Article in press: December 12, 2017
Published online: January 21, 2018
Processing time: 71 Days and 5.8 Hours
Probiotics have been approved to be used to relieve irritable bowel syndrome (IBS), and Lactobacillus rhamnosus GG (LGG) is the best studied member of lactic acid bacteria and has supportive therapeutic efficacy in IBS. However, the mechanism remains a significant challenge to researchers. This study developed a PI-IBS model to evaluate the effect of LGG supernatant on serotonin transporter expression.
This study is a part of a National Natural Science Foundation of China project. On the basis of developing an experimental model of PI-IBS, this research explored the effect of LGG-s on SERT levels in intestinal and brain tissues.
This study detected the expression levels of SERT mRNA and SERT-P to evaluate the effect of LGG-s in PI-IBS rats, which were infected with C. jejuni. LGG-s could up-regulate SERT mRNA and SERT-P levels in rat intestinal tissues but had no influence in rat brain tissues. The more detailed research on LGG-s will contribute to more accurate treatment of IBS.
The model group of PI-IBS (n = 85) was given C. jejuni (1010 CFU/mL, 2 mL/d per rat) for 7 d, then the body weight of the rats and the relative content of stool water were measured to evaluate the phase of infection, and the fresh stool specimens were cultured for the presence of C. jejuni on Campylobacter selective agar plates. After the model evaluation, the rats were regrouped, and each group was gavaged with different concentrations of LGG-s. The treatments were maintained for 1.0, 2.0, 3.0 or 4.0 wk during the experiment. Then, SERT expression was detected by RT-PCR and Western blot to evaluate the effect of LGG-s.
The levels of SERT mRNA and SERT-P in intestinal tissues were up-regulated by treatment with LGG-s of different concentrations. Triple-diluted LGG-s showed a more significant difference within a short term, while, in the long run, undiluted and double-diluted LGG-s proved better. However, there were no significant differences in SERT mRNA and SERT-P in the brain tissues between each group, with or without treatment with LGG-s. Some factors and differences in the contents of various substances (proteins, fatty acids, inorganic salts, etc.) in the supernatant may induce a different increase in SERT levels. More detailed research about LGG-s is needed.
This study demonstrates that LGG-s up-regulates SERT expression in intestinal tissues, but has no statistical effect in brain tissues in PI-IBS rats. The previous study has proved that LGG-s could up-regulate the SERT levels in intestinal tissues in healthy mice. Moreover, LGG-s led to dose-dependent expression of SERT. The contents of substances in the supernatant, combined with their different concentrations, molecular mass, and previous C. jejuni infection, may result in this phenomenon. Therefore, more detailed research about LGG-s and relief of clinical symptoms with the treatment of LGG-s would be done in our next work.
The infection with C. jejuni could help to build a PI-IBS model with lower expression of SERT. For the future accurate treatment of IBS, proteomics analysis of LGG-s is important and urgent.